Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14QXP | ISIN: FR0012127173 | Ticker-Symbol: 6OP
Tradegate
06.06.25 | 09:05
6,000 Euro
-0,50 % -0,030
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OSE IMMUNOTHERAPEUTICS SA Chart 1 Jahr
5-Tage-Chart
OSE IMMUNOTHERAPEUTICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
5,9205,93017:07
5,9205,93017:04

Aktuelle News zur OSE IMMUNOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoOSE Immunotherapeutics - New UC biomarker underpins growth strategy171OSE has announced plans to strengthen its growth strategy and accelerate the key pillars of its pipeline, covering immuno-inflammation and immuno-oncology. In the inflammation space, the company revealed...
► Artikel lesen
MiOse Immunotherapeutics: Documents made available to the shareholders for the combined general meeting of June 25th, 20253
MiOSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology182OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology Ignites strong momentum in immunology & inflammation pipeline through lusvertikimab...
► Artikel lesen
DiOSE Immunotherapeutics - ASCO 2025 update showcases Tedopi potential204OSE Immunotherapeutics presented multiple updates at the 61st Annual American Society of Clinical Oncology Conference (ASCO 2025) related to Tedopi, its proprietary off-the-shelf neoepitope-based cancer...
► Artikel lesen
MoOSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi in Pancreatic Cancer and Non-Small Cell Lung Cancer267OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer Two presentations at the American Society of Clinical...
► Artikel lesen
23.05.OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPa Blockade in Two Ongoing Trials at ASCO 2025214OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPa Blockade in Two Ongoing Trials...
► Artikel lesen
22.05.OSE Immunotherapeutics - Strategic collaboration in mRNA technologies270OSE Immunotherapeutics has announced a new strategic collaboration with Inside Therapeutics and MiNT Laboratory (University of Angers) to develop mRNA therapies and accelerate nanodrug development....
► Artikel lesen
OSE IMMUNOTHERAPEUTICS Aktie jetzt für 0€ handeln
21.05.France invests €1.3M into novel mRNA project led by OSE Immunotherapeutics2
21.05.OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies331OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies OSE Immunotherapeutics to lead French consortium with Inside Therapeutics and MiNT Laboratory (University...
► Artikel lesen
06.05.OSE Immunotherapeutics - Lusvertikimab impresses in extension period data300OSE Immunotherapeutics has presented new data for lusvertikimab in ulcerative colitis (UC), with encouraging results from the extension period of the Phase II CoTikiS trial. The key takeaway was that...
► Artikel lesen
05.05.OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab70OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab Lusvertikimab well tolerated over the 24-week additional treatment period.Oral...
► Artikel lesen
30.04.OSE Immunotherapeutics: Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025263Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025 New gene expression signature for cancer patients to predict clinical response...
► Artikel lesen
23.04.OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 20251
09.04.OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 20252
03.04.OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 20252
03.04.OSE Immunotherapeutics - Primed for value appreciation324OSE Immunotherapeutics is a clinical-stage immuno-oncology and immuno-inflammation company, with a pipeline spanning all stages of development. The company recently reported its FY24 results, reflecting...
► Artikel lesen
26.03.OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update87OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Total income of €83.4 million. Cash level of €64.2 million1 as of December 31, 2024, ensuring financial...
► Artikel lesen
12.03.OSE Immunotherapeutics - Tedopi shows promise in pancreatic cancer324OSE Immunotherapeutics has reported positive top-line data from the investigator-sponsored Phase II trial assessing Tedopi in combination with FOLFIRI (a three-drug chemotherapy regimen made up of folinic...
► Artikel lesen
11.03.OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi) in Advanced Pancreatic Cancer154OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer Primary endpoint met in randomized...
► Artikel lesen
07.03.OSE Immunotherapeutics - KOL event highlights lusvertikimab's potential350OSE Immunotherapeutics and Edison held a key opinion leader (KOL) event on 5 March 2025, providing up-to-date insights into OSE's lead immuno-inflammation candidate, lusvertikimab, following the European...
► Artikel lesen
Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1